China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Com...(in China. Its facility is one of the few...)

Date:3/12/2008

in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company has two drugs on the market and has received China SFDA licenses for research and clinical development of seven more medications such as Oxycodone, Tilidine and Pholcodine. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. You are urged to read the Company's filings with the Securities and Exchange Commission, including, but not limited to, the risk factors contained therein. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

CONTACT

Dr. Hui Shao

Senior Vice President

China Aoxing Pharmaceutical

201-420-1075

'/>"/>

SOURCE China Aoxing Pharmaceutical Company, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Pharmaxis First Steps into China
2. Hovione Buys Drug Manufacturing Facility in China
3. China Nepstar Chain Drugstore to Acquire 18 Stores from Dongguan Hui Ren Tang Pharmaceutical Co.
4. China Yingxia International Announces Q4 and FY 2007 Estimates
5. China Biologic Products Commences Trading on OTC Bulletin Board
6. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
7. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
8. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
9. China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group
10. China Pharma Appoints Three Independent Non-Executive Directors
11. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results